{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:39:38Z","timestamp":1771234778113,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["71874209"],"award-info":[{"award-number":["71874209"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2019JJ40411"],"award-info":[{"award-number":["2019JJ40411"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10067-021-05876-4","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T23:29:17Z","timestamp":1628551757000},"page":"63-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis"],"prefix":"10.1007","volume":"41","author":[{"given":"Chongqing","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sini","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liubao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuxia","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"issue":"10093","key":"5876_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390(10093):457\u2013468. https:\/\/doi.org\/10.1016\/S0140-6736(17)31618-5","journal-title":"Lancet"},{"issue":"10055","key":"5876_CR2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023\u20132038. https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"issue":"7","key":"5876_CR3","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T et al (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73(7):1316\u20131322. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204627","journal-title":"Ann Rheum Dis"},{"issue":"9746","key":"5876_CR4","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376(9746):1094\u20131108. https:\/\/doi.org\/10.1016\/S0140-6736(10)60826-4","journal-title":"Lancet"},{"issue":"4","key":"5876_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/rheumatology\/ker370","volume":"51","author":"R Li","year":"2012","unstructured":"Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW et al (2012) Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford) 51(4):721\u2013729. https:\/\/doi.org\/10.1093\/rheumatology\/ker370","journal-title":"Rheumatology (Oxford)"},{"key":"5876_CR6","unstructured":"Documentation of the Second China National Samples Survey on Disability. China Statistics Press; 2007."},{"issue":"7","key":"5876_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/1756-185X.12754","volume":"18","author":"CS Lau","year":"2015","unstructured":"Lau CS, Chia F, Harrison A, Hsieh TY, Jain R, Jung SM et al (2015) APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis 18(7):685\u2013713. https:\/\/doi.org\/10.1111\/1756-185X.12754","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"5876_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3760\/cma.j.issn.0578-1426.2018.04.004","volume":"57","author":"RA Chinese","year":"2018","unstructured":"Chinese RA (2018) 2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis. Zhonghua Nei Ke Za Zhi 57(4):242\u2013251. https:\/\/doi.org\/10.3760\/cma.j.issn.0578-1426.2018.04.004","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"1","key":"5876_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 68(1):1\u201326. https:\/\/doi.org\/10.1002\/art.39480","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"5876_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5876_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jval.2019.12.003","volume":"23","author":"S Ghabri","year":"2020","unstructured":"Ghabri S, Binard A, Pers YM, Maunoury F, Caro JJ (2020) Economic evaluation of sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis and inadequate response or intolerance to methotrexate in France. Value Health 23(4):461\u2013470. https:\/\/doi.org\/10.1016\/j.jval.2019.12.003","journal-title":"Value Health"},{"issue":"8","key":"5876_CR12","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1093\/rheumatology\/kev014","volume":"54","author":"X Zhang","year":"2015","unstructured":"Zhang X, Mu R, Wang X, Xu C, Duan T, An Y et al (2015) The impact of rheumatoid arthritis on work capacity in Chinese patients: a cross-sectional study. Rheumatology (Oxford) 54(8):1478\u20131487. https:\/\/doi.org\/10.1093\/rheumatology\/kev014","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"5876_CR13","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s12325-021-01733-7","volume":"38","author":"C Tan","year":"2021","unstructured":"Tan C, Li S, Yi L, Zeng X, Peng L, Qin S et al (2021) Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in China: a cost-effectiveness analysis based on a mapping algorithm derived from a Chinese population. Adv Ther 38(5):2571\u20132585. https:\/\/doi.org\/10.1007\/s12325-021-01733-7","journal-title":"Adv Ther"},{"issue":"6","key":"5876_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40273-018-00765-2","volume":"37","author":"D Incerti","year":"2019","unstructured":"Incerti D, Curtis JR, Shafrin J, Lakdawalla DN, Jansen JP (2019) A flexible open-source decision model for value assessment of biologic treatment for rheumatoid arthritis. Pharmacoeconomics 37(6):829\u2013843. https:\/\/doi.org\/10.1007\/s40273-018-00765-2","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"5876_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159(4):253\u2013261. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00006","journal-title":"Ann Intern Med"},{"issue":"22","key":"5876_CR16","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.4103\/0366-6999.245157","volume":"131","author":"ZG Li","year":"2018","unstructured":"Li ZG, Liu Y, Xu HJ, Chen ZW, Bao CD, Gu JR et al (2018) Efficacy and safety of tofacitinib in chinese patients with rheumatoid arthritis. Chin Med J (Engl) 131(22):2683\u20132692. https:\/\/doi.org\/10.4103\/0366-6999.245157","journal-title":"Chin Med J (Engl)"},{"key":"5876_CR17","unstructured":"2015 report on Chinese nutrition and chronic disease. [database on the Internet]. The National Health and Family Planning Commission. Available from: http:\/\/www.gov.cn\/xinwen\/2015-06\/30\/content_2887030.htm"},{"issue":"1","key":"5876_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10067-016-3424-5","volume":"36","author":"Y An","year":"2017","unstructured":"An Y, Liu T, He D, Wu L, Li J, Liu Y et al (2017) The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study. Clin Rheumatol 36(1):35\u201343. https:\/\/doi.org\/10.1007\/s10067-016-3424-5","journal-title":"Clin Rheumatol"},{"issue":"12","key":"5876_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s40273-020-00961-z","volume":"38","author":"L Tian","year":"2020","unstructured":"Tian L, Xiong X, Guo Q, Chen Y, Wang L, Dong P et al (2020) Cost-effectiveness of tofacitinib for patients with moderate-to-severe rheumatoid arthritis in China. Pharmacoeconomics 38(12):1345\u20131358. https:\/\/doi.org\/10.1007\/s40273-020-00961-z","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"5876_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jval.2014.10.013","volume":"18","author":"JJ Carlson","year":"2015","unstructured":"Carlson JJ, Ogale S, Dejonckheere F, Sullivan SD (2015) Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. Value Health 18(2):173\u2013179. https:\/\/doi.org\/10.1016\/j.jval.2014.10.013","journal-title":"Value Health"},{"issue":"4","key":"5876_CR21","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7(4):R796-806. https:\/\/doi.org\/10.1186\/ar1740","journal-title":"Arthritis Res Ther"},{"issue":"5 Suppl 39","key":"5876_CR22","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23(5 Suppl 39):S100\u2013S108","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"5876_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40744-017-0078-y","volume":"4","author":"V Strand","year":"2017","unstructured":"Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J (2017) Discontinuation of Biologic therapy in rheumatoid arthritis: analysis from the Corrona RA Registry. Rheumatol Ther 4(2):489\u2013502. https:\/\/doi.org\/10.1007\/s40744-017-0078-y","journal-title":"Rheumatol Ther"},{"key":"5876_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"5876_CR25","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/acr.20643","volume":"63","author":"J Zhang","year":"2011","unstructured":"Zhang J, Shan Y, Reed G, Kremer J, Greenberg JD, Baumgartner S et al (2011) Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis Care Res (Hoboken) 63(12):1672\u20139. https:\/\/doi.org\/10.1002\/acr.20643","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"35","key":"5876_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20350","volume":"20","author":"M Stevenson","year":"2016","unstructured":"Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J et al (2016) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess 20(35):1\u2013610. https:\/\/doi.org\/10.3310\/hta20350","journal-title":"Health Technol Assess"},{"key":"5876_CR27","doi-asserted-by":"publisher","unstructured":"Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011(2):CD008794. https:\/\/doi.org\/10.1002\/14651858.CD008794.pub2","DOI":"10.1002\/14651858.CD008794.pub2"},{"key":"5876_CR28","doi-asserted-by":"publisher","unstructured":"Tosh J, Brennan A, Wailoo A, Bansback N (2011) The Sheffield rheumatoid arthritis health economic model. Rheumatology (Oxford). 2011;50 Suppl 4:iv26\u201331. https:\/\/doi.org\/10.1093\/rheumatology\/ker243","DOI":"10.1093\/rheumatology\/ker243"},{"issue":"4","key":"5876_CR29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/art.23374","volume":"58","author":"AJ Wailoo","year":"2008","unstructured":"Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F (2008) Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum 58(4):939\u2013946. https:\/\/doi.org\/10.1002\/art.23374","journal-title":"Arthritis Rheum"},{"issue":"2","key":"5876_CR30","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1186\/ar2944","volume":"12","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, Michaud K (2010) The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 12(2):R35. https:\/\/doi.org\/10.1186\/ar2944","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"5876_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/acr.20405","volume":"63","author":"K Michaud","year":"2011","unstructured":"Michaud K, Wallenstein G, Wolfe F (2011) Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients. Arthritis Care Res (Hoboken) 63(3):366\u2013372. https:\/\/doi.org\/10.1002\/acr.20405","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5876_CR32","unstructured":"Life tables for WHO member states (2016) World Health Organization, Geneva"},{"issue":"6","key":"5876_CR33","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/art.11024","volume":"48","author":"F Wolfe","year":"2003","unstructured":"Wolfe F, Michaud K, Gefeller O, Choi HK (2003) Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 48(6):1530\u20131542. https:\/\/doi.org\/10.1002\/art.11024","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5876_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3899\/jrheum.110491","volume":"39","author":"K Michaud","year":"2012","unstructured":"Michaud K, Vera-Llonch M, Oster G (2012) Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis. J Rheumatol 39(1):54\u201359. https:\/\/doi.org\/10.3899\/jrheum.110491","journal-title":"J Rheumatol"},{"issue":"10","key":"5876_CR35","doi-asserted-by":"publisher","first-page":"e47373","DOI":"10.1371\/journal.pone.0047373","volume":"7","author":"B Wu","year":"2012","unstructured":"Wu B, Wilson A, Wang FF, Wang SL, Wallace DJ, Weisman MH et al (2012) Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in China. PLoS ONE 7(10):e47373. https:\/\/doi.org\/10.1371\/journal.pone.0047373","journal-title":"PLoS ONE"},{"key":"5876_CR36","unstructured":"Health care and personal articles of consumer price indices. In: indices Hcapaocp, editor.: Health care and personal articles of consumer price indices."},{"issue":"2","key":"5876_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10165-006-0461-y","volume":"16","author":"M Tanno","year":"2006","unstructured":"Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M et al (2006) Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol 16(2):77\u201384. https:\/\/doi.org\/10.1007\/s10165-006-0461-y","journal-title":"Mod Rheumatol"},{"key":"5876_CR38","unstructured":"China statistical yearbook 2020. National Bureau of Statistics of China."},{"issue":"7","key":"5876_CR39","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/13696998.2017.1307205","volume":"20","author":"JP Jansen","year":"2017","unstructured":"Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B et al (2017) Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ 20(7):703\u2013714. https:\/\/doi.org\/10.1080\/13696998.2017.1307205","journal-title":"J Med Econ"},{"issue":"10","key":"5876_CR40","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1200\/JCO.2013.53.1186","volume":"32","author":"S Djalalov","year":"2014","unstructured":"Djalalov S, Beca J, Hoch JS, Krahn M, Tsao MS, Cutz JC et al (2014) Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol 32(10):1012\u20131019. https:\/\/doi.org\/10.1200\/JCO.2013.53.1186","journal-title":"J Clin Oncol"},{"issue":"11","key":"5876_CR41","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.18553\/jmcp.2014.20.11.1086","volume":"20","author":"YH Bae","year":"2014","unstructured":"Bae YH, Mullins CD (2014) Do value thresholds for oncology drugs differ from nononcology drugs? J Manag Care Spec Pharm 20(11):1086\u201392. https:\/\/doi.org\/10.18553\/jmcp.2014.20.11.1086","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"5876_CR42","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.eururo.2017.07.041","volume":"73","author":"M Sarfaty","year":"2018","unstructured":"Sarfaty M, Leshno M, Gordon N, Moore A, Neiman V, Rosenbaum E et al (2018) Cost effectiveness of nivolumab in advanced renal cell carcinoma. Eur Urol 73(4):628\u2013634. https:\/\/doi.org\/10.1016\/j.eururo.2017.07.041","journal-title":"Eur Urol"},{"key":"5876_CR43","unstructured":"China Guidelines for Pharmacoeconomic Evaluations (2020). Chinese Pharmaceutical Association; 2020."},{"key":"5876_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2018.10.004","volume":"43","author":"X Wan","year":"2019","unstructured":"Wan X, Zhang Y, Ma J, Tan C, Zeng X, Peng L (2019) Ribociclib in hormone-receptor-positive advanced breast cancer: establishing a value-based cost in China. Breast 43:1\u20136. https:\/\/doi.org\/10.1016\/j.breast.2018.10.004","journal-title":"Breast"},{"issue":"14","key":"5876_CR45","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1002\/cncr.30666","volume":"123","author":"XM Wan","year":"2017","unstructured":"Wan XM, Peng LB, Ma JA, Li YJ (2017) Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives. Cancer 123(14):2634\u20132641. https:\/\/doi.org\/10.1002\/cncr.30666","journal-title":"Cancer"},{"issue":"5","key":"5876_CR46","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.21037\/tlcr-19-605","volume":"9","author":"B Wu","year":"2020","unstructured":"Wu B, Lu S (2020) The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. Transl Lung Cancer Res 9(5):1770\u201384. https:\/\/doi.org\/10.21037\/tlcr-19-605","journal-title":"Transl Lung Cancer Res"},{"issue":"7","key":"5876_CR47","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3899\/jrheum.160941","volume":"44","author":"MD Stevenson","year":"2017","unstructured":"Stevenson MD, Wailoo AJ, Tosh JC, Hernandez-Alava M, Gibson LA, Stevens JW et al (2017) The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate. J Rheumatol 44(7):973\u2013980. https:\/\/doi.org\/10.3899\/jrheum.160941","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05876-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05876-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05876-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T16:17:20Z","timestamp":1641313040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05876-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5876"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05876-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"assertion":[{"value":"19 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}